Antiretroviral Drug Pharmacokinetics in Hepatitis with Hepatic Dysfunction
Open Access
- 1 January 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (1) , 174-181
- https://doi.org/10.1086/426021
Abstract
Chronic viral hepatitis is common among persons with HIV-1 infection, because of shared modes of transmission, and coinfection results in acceleratedKeywords
This publication has 41 references indexed in Scilit:
- Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis CAIDS, 2004
- Short Communication: Interactions between Nevirapine Plasma Levels, Chronic Hepatitis C, and the Development of Liver Toxicity in HIV-Infected PatientsAIDS Research and Human Retroviruses, 2003
- Mortality due to Liver Failure and Impact on Survival of Hepatitis Virus Infections in HIV-Infected Patients Receiving Potent Antiretroviral TherapyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infectionsHepatology, 2002
- AbacavirDrugs, 2000
- Effects of Liver Disease on PharmacokineticsClinical Pharmacokinetics, 1999
- Clinical Pharmacokinetics of StavudineClinical Pharmacokinetics, 1997
- Clinical Pharmacokinetics of ZidovudineClinical Pharmacokinetics, 1996
- Antipyrine clearance and metabolite excretion in patients with chronic hepatitis CJournal of Hepatology, 1995
- DidanosineDrugs, 1992